Paul Grayson, Tentarix CEO (Versant)
October 15, 2021 08:35 AM EDT
Financing

Phar­ma vet­er­ans re­group with $50M and a plan to dis­cov­er new mul­ti-specifics

Nicole DeFeudis

Editor

While a horde of drug­mak­ers de­vel­ops bis­pe­cif­ic an­ti­bod­ies to more di­rect­ly tar­get tu­mor cells — there were about 100 pro­grams in or near­ing clin­i­cal tri­als …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times